Search Results
Your search for The A matches 31879 pages
Showing 1951 - 2000Primary Care Intervention to Improve Follow-up of Overdue Abnormal Cancer Screening Test Results
In a study reported in JAMA, Atlas et al found that a primary care intervention including electronic health record (EHR) reminders and patient outreach with or without patient navigation improved timeliness of follow-up of overdue abnormal cancer screening test results. Study Details The open-label ...
FDA Approves Ivosidenib for Myelodysplastic Syndromes
On October 24, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test. The FDA also approved the...
CMS, Congress Must Work Together to Support Access to Cancer Care and Physician Practice Health
In letters to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) commented on provisions that impact cancer care for Medicare beneficiaries in the 2024 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule, as well...
ASCO Response to Drug Shortages Request for Information
The Association for Clinical Oncology (ASCO) responded to a bicameral Request for Information (RFI) on the underlying factors driving drug shortages. The Association’s comments highlighted the impact of the shortages on patient care and pointed to economic failures and supply chain vulnerabilities...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Annual Report to the Nation on COVID-19’s Impact on Cancer Diagnosis Finds Sharp Declines in New Diagnoses of Six Major Cancers
Findings from the Annual Report to theNation on the Status of Cancer, Part 2: Early Assessment of the COVID-19 Pandemic’s Impact on Cancer Diagnosis show new diagnoses of six major cancer types in the United States fell sharply between March and May 2020, coinciding with the beginning of the...
Diagnosis of Cardiovascular Disease and Risk of Subsequent Incident Cancer Diagnosis
In a retrospective cohort study reported in JACC: CardioOncology, Caitlin F. Bell, MD, of the Division of Cardiovascular Medicine, Stanford University School of Medicine, and colleagues found that persons with a diagnosis of cardiovascular disease (CVD) were more likely to have a subsequent...
Expert Point of View: Matthew Hatton, MBChB, MSc, FRCP, FRCR and Charles Simone, MD
Invited discussant Matthew Hatton, MBChB, MSc, FRCP, FRCR, a consultant and Honorary Professor in Clinical Oncology at Weston Park Cancer Center, Sheffield, UK, pointed out that the original analysis of RTOG 0617 was disappointing and failed to find evidence that intensity-modulated radiation...
Comparing Two Radiation Therapy Techniques for Locally Advanced NSCLC: Focus on Toxicity
Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non–small cell lung cancer (NSCLC), according to a planned long-term prospective...
Expert Point of View: Helena Linardou, MD, PhD
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, was invited as the discussant of the studies on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Preliminary Data Dr. Linardou...
Role of TROP-2–Directed Antibody-Drug Conjugates With Immune Checkpoint Inhibitors in Advanced NSCLC
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way
Gender diversity, equity, and inclusion (DEI) in medicine has long been acknowledged as more than “the right thing to do,” with clear evidence of benefits in innovation, collaboration, and workplace culture.1 Yet the data continue to showcase challenges in achieving these goals despite women...
University of Arizona Welcomes Thoracic Surgeon Praveen Sridhar, MD
The University of Arizona College of Medicine–Tucson Department of Surgery is pleased to welcome Praveen Sridhar, MD, as Clinical Associate Professor in the Department of Surgery’s Division of Cardiothoracic Surgery. Dr. Sridhar, who is particularly interested in thoracic oncology and minimally...
Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present
I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...
Breakthrough Prize, ‘Oscars of Science,’ Celebrates 2024 Laureates in Life Sciences
On September 14, 2023, the Breakthrough Prize Foundation announced the winners of the 2024 awards, honoring an esteemed group of the world’s researchers for their impactful scientific discoveries, including a subset responsible for substantial progress in the understanding and treatment of major...
From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...
Expert Point of View: Helena Linardou, MD, PhD
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, served as discussant of the session on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Calling antibody-drug conjugates “the next...
HERTHENA-Lung01: Antitumor Activity Shown With HER3-DXd in EGFR-Mutated NSCLC
The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. In the phase II HERTHENA-Lung01 trial, the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan...
Patient Education Materials on Breast Cancer May Be Difficult to Access
Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...
AI-Based Calculator May Accurately Predict Long-Term Cancer Survival
Researchers have developed a novel artificial intelligence (AI)-based Cancer Survival Calculator for estimating long-term survival in patients with newly diagnosed cancer, according to new findings presented by Janczewski et al at the American College of Surgeons (ACS) Clinical Congress 2023....
Novel Strategies for Eliminating Dormant Tumor Cells in Breast Cancer Survivors
Researchers have discovered that it may be possible to detect and treat dormant tumor cells in breast cancer survivors, according to new findings presented by DeMichele et al at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract 244MO). The results may have offered a...
Adults Living Alone Are at Higher Risk of Cancer Mortality Compared to Adults Living With Others
Adults living alone had a 32% higher risk of cancer death than those living with others, according to study results from researchers at the American Cancer Society. For men, the risk was even greater—38%—compared to a 30% higher risk for women. The association between living alone and cancer...
PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...
Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of...
Germline Cancer-Predisposing Variants and Increased Risk of Late Mortality From Subsequent Malignant Neoplasms in Long-Term Childhood Cancer Survivors
In an analysis from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Chen et al found that among long-term survivors of childhood cancers, carriers of germline cancer-predisposing variants were at an increased risk of late mortality...
Trends in Lung Cancer Incidence Among Women and Men in the United States
In a study reported in a research letter in JAMA Oncology, Jemal et al found that rates of lung cancer declined more in men vs women in the United States in recent years, such that incidence is now higher in women vs men aged ≤ 55 years. As stated by the investigators, “A previous study from the...
Induction Chemotherapy and Subsequent Chemoradiation May Improve Survival and Recurrence Rates in Patients With Cervical Cancer
Researchers have found that a short course of induction chemotherapy prior to chemoradiation may be effective at reducing the rate of relapse and mortality among patients with locally advanced cervical cancer, according to new preliminary findings presented by McCormack et al at the European...
Nivolumab Plus Gemcitabine and Cisplatin May Improve Survival in Patients With Metastatic Urothelial Carcinoma
Researchers have found that nivolumab in combination with a chemotherapy regimen may improve the rate of survival in patients with metastatic urothelial carcinoma, according to new findings simultaneously published by van der Heijden et al in The New England Journal of Medicine and presented at the ...
Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial
The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...
Erdafitinib Demonstrates Improved Responses in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with advanced or metastatic urothelial carcinoma with FGFR alterations. Results from the phase III THOR trial, led by...
ESMO 2023: New Data in Skin Cancers
At the European Society for Medical Oncology (ESMO) Congress 2023, new findings are being presented in cutaneous squamous cell carcinoma, late-stage melanoma, and refractory melanoma brain metastases. Presurgical Immunotherapy in Advanced Operable Cutaneous Squamous Cell Carcinoma Patients with...
PARP inhibitor Plus Immunotherapy Added to Chemotherapy Lowers Risk of Disease Progression in Patients With Advanced Endometrial Cancer
Immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in the...
Belzutifan Improves Outcomes for Pretreated Patients With Clear Cell Renal Cell Carcinoma Compared to Everolimus
The hypoxia-inducible factor (HIF)-2α inhibitor belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma in patients previously treated with immune checkpoint inhibitors and antiangiogenic therapies compared with everolimus. The phase III LITESPARK-005 trial, led...
FDA Expands Pediatric Indication for Entrectinib and Approves New Pellet Formulation
On October 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule tyrosine kinase inhibitor entrectinib (Rozlytrek) for pediatric patients aged 1 month and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion...
EVEREST Trial: Adjuvant Everolimus for High-Risk Clear Cell Renal Cell Carcinoma
A secondary analysis from the phase III SWOG S0931 EVEREST trial found patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectomy who received adjuvant everolimus had a statistically significant improvement in recurrence-free survival compared to patients who...
Pre- and Postsurgical Immunotherapy Improves Outcomes for Patients With Resectable Early-Stage NSCLC
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...
Is Idecabtagene Vicleucel Effective in Patients With Multiple Myeloma, Regardless of Race?
The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel may offer an overall survival benefit in patients with multiple myeloma, regardless of their race or ethnicity, according to a novel study published by Peres et al in Blood Advances. Background Multiple myeloma—a cancer of...
Patients and Survivors of Cancer May Be Impacted by U.S. Drug Shortages
The drug shortage crisis in the United States may continue to impact the care of 10% of patients and survivors of cancer, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Findings In the new survey, researchers asked 1,222 patients and survivors of...
Tislelizumab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In the phase III RATIONALE-301 trial reported in JAMA Oncology, Shukui Qin, MD, PhD, and colleagues found that tislelizumab was noninferior to sorafenib in terms of overall survival as first-line treatment for patients with unresectable hepatocellular carcinoma. Study Details In the open-label...
Efficacy of Radiotherapy in Rhabdomyosarcoma
In an analysis of data from two clinical trials and a soft-tissue sarcoma registry reported in the Journal of Clinical Oncology, Koscielniak et al identified which patients aged ≤ 21 years with localized rhabdomyosarcoma appeared to derive benefit from radiation therapy. Study Details The study...
Blood-Based Testing for Multicancer Early Detection
In a prospective cohort study (PATHFINDER) reported in The Lancet, Deb Schrag, MD, MPH, FASCO, and colleagues evaluated the performance of blood-based testing for multicancer early detection in adults without signs or symptoms of cancer. As stated by the investigators, “Multicancer early detection ...
Almost Half of Oncology Drugs Approved Since 1998 Have Been Precision Therapies, New Study Finds
Among the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% of them were precision therapies, according to a recent study published by Suehnholz et al in Cancer Discovery. Background Precision oncology therapies often require...
Combination of Ceralasertib and Durvalumab Shows Activity in Phase II Trial of Advanced NSCLC
The combination of the ATR inhibitor ceralasertib and the immune checkpoint inhibitor durvalumab has demonstrated notable survival rates and clinical benefits among patients who have advanced non–small cell lung cancer (NSCLC) with RAS mutations, according to data presented at the International...
MRI Scans Could Predict Postradiation Urinary Side Effects in Patients With Prostate Cancer
Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...
CNS Prophylaxis With High-Dose Methotrexate in High-Risk Aggressive B-Cell Lymphoma
In a retrospective study reported in the Journal of Clinical Oncology, Lewis et al found that prophylactic high-dose methotrexate did not appear to offer a clinically meaningful reduction in risk of central nervous system (CNS) disease progression in patients with high-risk aggressive B-cell...
Air Pollution and Breast Cancer Risk: Residential and Workplace Exposure
Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas. Results of a study looking at the effects of both residential and workplace exposure to air pollution on breast cancer risk ...
Gut Microbiome Variations and Colorectal Cancer Risk
Researchers have identified significant variations in the gut microbiome of patients with precancerous colorectal lesions, suggesting a potential correlation between gut bacteria and the onset of precancerous lesions and colorectal cancer, according to new findings presented by Gacesa et al at...
The Future of AI in Cancer Care
New research has illustrated the strides being made to apply modern artificial intelligence (AI) computing methods to oncology, according to new findings to be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Background Researchers have long investigated the potential of ...
Do Low- and Moderate-Grade Adverse Events Affect Rates of Treatment Discontinuation in CLL?
In an analysis from the phase III ECOG/ACRIN E1912 trial in chronic lymphocytic leukemia (CLL) published in the Journal of Clinical Oncology, O’Connell et al found that grade 1 and 2 adverse events were significant contributors to patient-reported side-effects bother, with grade 2 events being...
Addition of Berzosertib to Topotecan in Relapsed SCLC
In a phase II trial reported in JAMA Oncology, Takahashi et al found that the addition of the ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor berzosertib to topotecan did not improve progression-free survival in patients with relapsed small cell lung cancer (SCLC). However, an overall ...
